跳到正文
原文
NEJM· @NEJM · X·· 14 天前精选AI 评分80
AI 导读

NEJM发布OBERON和TITANIA两项重复III期试验结果,在接受吸入维持治疗的COPD患者中,加用tozorakimab的中重度急性加重发生率低于安慰剂。完整结果与研究摘要见 https://nej.md/4zNqtWJ。

推荐理由

两项重复III期试验显示,在吸入维持治疗基础上加用tozorakimab可降低COPD中重度急性加重发生率,为抗体治疗COPD再添一项对照数据。

正文

In two replicate phase 3 trials involving patients with COPD who were receiving inhaled maintenance therapy, add-on tozorakimab resulted in a lower rate of moderate or severe exacerbations than placebo. Full results of the OBERON and TITANIA trials and Research Summary: https://nej.md/4zNqtWJ

来源:NEJM · x.com